![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Identification and Treatment of Multiple Subtypes of HCV Genotype 4 in the PEARL-I Study With Ombitasvir and ABT-450/r ± Ribavirin
|
|
|
Reported by Jules Levin
AASLD Nov 7-11 Boston
Gretja Schnell, Rakesh Tripathi, Jill Beyer, Thomas Reisch, Preethi Krishnan, Tolga Baykal, Coleen Hall, Regis A Vilchez, Tami Pilot-Matias, and Christine Collins
Research & Development, AbbVie Inc., North Chicago, Illinois, United States
AASLD: Interferon-Free Regimens of Ombitasvir and ABT-450/r With or Without Ribavirin in Patients With HCV Genotype 4 Infection: PEARL-I Study Results - (12/01/14)
![AASLD1.gif](../images/121714/121714-4/AASLD1.gif)
![AASLD2.gif](../images/121714/121714-4/AASLD2.gif)
![AASLD3.gif](../images/121714/121714-4/AASLD3.gif)
![AASLD4.gif](../images/121714/121714-4/AASLD4.gif)
![AASLD5.gif](../images/121714/121714-4/AASLD5.gif)
![AASLD6.gif](../images/121714/121714-4/AASLD6.gif)
![AASLD7.gif](../images/121714/121714-4/AASLD7.gif)
![AASLD8.gif](../images/121714/121714-4/AASLD8.gif)
![AASLD9.gif](../images/121714/121714-4/AASLD9.gif)
![AASLD10.gif](../images/121714/121714-4/AASLD10.gif)
![AASLD11.gif](../images/121714/121714-4/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|